drugset / Trial / NCT00117247

A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects

NCT00117247

Phase 1/2 Completed Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the single dose pharmacokinetics (PK) of subcutaneous (SC) darbepoetin alfa in subjects with congestive heart failure (CHF) and anemia.

Timeline

Start
2002-06
Primary completion
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic Subcutaneous